Video

Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

Author(s):

Shaji Kumar, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Related Content
The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/8

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Anitocabtagene Autoleucel in Multiple Myeloma | Image credit: © Nittaya – stock.adobe.com
December 11th 2024

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM

Ide-cel in multiple myeloma
December 10th 2024

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma